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Abstract
Background: We present our single center experience of 27 patients of hyperadrenergic
postural orthostatic tachycardia syndrome (POTS).
Methods: In a retrospective analysis, we reviewed the charts of 300 POTS patients being
followed at our autonomic center from 2003 to 2010, and found 27 patients eligible for
inclusion in this study. POTS was defined as symptoms of orthostatic intolerance (of greater
than six months’ duration) accompanied by a heart rate increase of at least 30 bpm (or a rate
that exceeds 120 bpm) that occurs in the first 10 min of upright posture or head up tilt test
(HUTT) occurring in the absence of other chronic debilitating disorders. Patients were diag-
nosed as having the hyperadrenergic form based on an increase in their systolic blood pressure
of ≥ 10 mm Hg during the HUTT (2) with concomitant tachycardia or their serum catecho-
lamine levels (serum norepinephnrine level ≥ 600 pg/mL) upon standing.
Results: Twenty seven patients, aged 39 ± 11 years, 24, (89%) of them female and 22 (82%)
Caucasian were included in this study. Most of these patients were refractory to most of the
first and second line treatments, and all were on multiple combinations of medications.
Conclusions: Hyperadrenergic POTS should be identified and differentiated from neuro-
pathic POTS. These patients are usually difficult to treat and there are no standardized
treatment protocols known at this time for patients with hyperadrenergic POTS. (Cardiol J
2011; 18, 5: 527–531)
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Introduction
Postural orthostatic tachycardia syndrome
(POTS) is characterized by symptoms of orthostatic
intolerance upon assuming an upright posture and
relief of these symptoms by recumbency [1, 2]. The
current definition of POTS is the presence of symp-
toms of orthostatic intolerance (> 6 months dura-
tion) associated with a heart rate (HR) increase of
30 bpm (or rate that exceeds 120 bpm) that occurs
within the first 10 min of standing or upright tilt, not
associated with other chronic debilitating conditions
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such as prolonged bed rest or the use of medications
known to diminish vascular or autonomic tone [1, 2].
In recent years there has been a substantial
improvement of our understanding of POTS.
Although the exact etiology remains elusive, we
know that the syndrome of postural tachycardia is
not a single clinical entity, but rather a heteroge-
neous group of various related clinical syndromes
having a final common presentation of orthostatic in-
tolerance.
The commonest form of POTS, called the neu-
ropathic or partial dysautonomic form, results from
neuropathy preferentially involving the lower ex-
tremities with resultant venous pooling [3–6]. An-
other group of patients suffer from centrally driven
abnormal sympathetic activation. This form of pos-
tural tachycardia syndrome is called hyperadrener-
gic POTS, and comprises about 10% of all POTS
patients. Patients suffering from hyperadrenergic
POTS have been observed to have an orthostatic
plasma norepinephrine level ≥ 600 pg/mL and a rise
of systolic blood pressure (SBP) of ≥ 10 mm Hg upon
standing [1, 2, 6–8]. We present our single center
experience of 27 hyperadrenergic POTS patients.
Methods
This was a retrospective study approved by our
local Institutional Review Board. We reviewed
charts of 300 POTS patients seen at our autonomic
center between 2003 and 2010 and found 27 patients
eligible for inclusion in this study.
Criterion for diagnosis of POTS
Postural orthostatic tachycardia was defined as
symptoms of orthostatic intolerance (of greater than
six months’ duration) accompanied by a HR increase
of at least 30 bpm (or a rate that exceeds 120 bpm)
observed during the first 10 min of upright posture
or head up tilt test (HUTT) occurring in the absence
of other chronic debilitating disorders [1, 2]. Symp-
toms include fatigue, orthostatic palpitations, exer-
cise intolerance, light-headedness, diminished con-
centration, headache, near-syncope and syncope. In
a retrospective chart review, we collected data in-
cluding demographic information, presenting symp-
toms, laboratory data, tilt-table response, and treat-
ment outcomes.
Criterion for diagnosis of hyperadrenergic
postural tachycardia syndrome
Patients were diagnosed as having the hyper-
adrenergic form based on an increase in their SBP
of  ≥ 10 mm Hg during the HUTT [2] with conco-
mitant tachycardia or their serum catecholamine
levels (serum norepinephnrine level ≥ 600 pg/mL)
upon standing [1, 2]. Each patient had been evalu-
ated for the presence of a pheochromocytoma by
a computed tomography scan of the abdomen, as well
as metaiodobenzylguanidine scanning. In no patient
was a pheochromocytoma detected.
HUTT protocol
The protocol used for tilt table testing has
been described elsewhere [1, 7, 9–12], but basi-
cally consisted of a 70-degree baseline upright tilt
for a period of 30 min, during which time HR and
blood pressure were monitored continually. If no
symptoms occurred, the patient was lowered to the
supine position and an intravenous infusion of iso-
proterenol started, with a dose sufficient to raise
the HR to 20–25% above the resting value. Upright
tilt was then repeated for 15 min. Patients were
included in the study if they had a POTS pattern
on HUTT (rise in HR without any change in blood
pressure).
Treatment protocols
The treatment protocols employed were based
on our previous experiences with orthostatic disor-
ders and are described in detail elsewhere [1, 7, 9–
–12]. Briefly, a sequence of therapies was employed
that included physical counter maneuvers and aero-
bic and resistance training, as well as increased die-
tary fluids and sodium. If these were ineffective,
pharmacotherapy was initiated in a sequence ge-
nerally consisting of beta-blockers, central sym-
patholytics, fludrocortisone, midodrine, and selec-
tive serotonin reuptake inhibitors, either alone or
in combination. As this was a retrospective chart
review, a formal questionnaire to assess the re-
sponse to treatment or an assessment of response
to treatment by HUTT testing was not employed.
Information about the subjective symptoms and
sense of well-being from each patient was collected
from the patient’s charts, physician communications
and direct patient inquiry. A treatment was conside-
red successful if it provided symptomatic relief.
Statistical analysis
Statistical analysis was done using SPSS15.
The data is observational and is presented as mean ±
± SD and percentages.
Results
Table 1 summarizes the clinical features, co-
morbid conditions, precipitating events and symp-
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toms of patients suffering from hyperadrenergic
POTS. Twenty seven patients aged 39 ± 11,
24 (89%) of them female and 22 (82%) of them Cauca-
sian were included in this study.
Precipitating events
The precipitating events in patients suffering
from hyperadrenergic POTS were pregnancy
(12.5%), viral infection (11.1%) and trauma (1%).
Comorbidity
Hypertension (33.3%), migraine (29.6%) and
joint hypermobility syndrome (18.5%) were com-
mon co-morbidities in this group of patients.
Symptoms of POTS
Dizziness and pre-syncope (60%) were the
common symptoms, followed by fatigue (51%) and
orthostatic palpitations (48%). Orthostatic hyper-
tension was seen in 19% of patients. Table 1 sum-
marizes other symptoms encountered in our patient
population.
Tilt table test
All patients demonstrated a typical hyperad-
renergic POTS response to the tilt table test. The
mean rise in HR on a tilt test was 35 ± 3 bpm and
the mean time to peak HR was 8 ± 3 min. The mean
increase in SBP was 13 ± 3 mm Hg.
Norephinephrine levels
The standing norepinephrine levels were cal-
culated in each patient. The mean norepinephrine
levels in these patients were 828 ± 200 pg/mL (nor-
mal range: 520 pg/mL).
Medications and response
to the medications
Most of these patients were on a combination
of medications. The algorithm we used has been de-
scribed in the ‘Methods’ section under ‘Treatment
protocol’. Most of these patients were receiving
a combination of various first and second line medi-
cations. These patients were refractory to various
combinations of medications. Table 2 summarizes
various medications we commonly used in these
patients.
Discussion
Our understanding of the disorder now called
POTS has substantially increased over the past two
decades. The early descriptions of the disorder fo-
cused on a group of patients who had been previous-
ly healthy until a sudden febrile illness (presumably
viral) brought on an abrupt onset of symptoms [3].
Table 2. Medication use and response to diffe-
rent medications used in patients with hyper-
adrenergic postural orthostatic tachycardia.
Medication Used in Response
patients to medication
Adderall 4/27 (14.8%) 4/4 (100%)
Florinef 4/27 (14.8%) 1/4 (25%)
Clonidine 12/27 (44.4%) 10/12 (83.3%)
Beta-blockers 24/27 (88.9%) 13/20 (65.0%)
Midodrine 9/27 (33.3%) 4/7 (57.1%)
SSRI 9/27 (33.3%) 3/7 (42.9%)
SSRI/NERI 17/27 (62.9%) 7/13 (53.9%)
Modafinil 5/27 (18.5%) 3/5 (60.0%)
Epogen 2/27 (7.4%) 1/2 (50.0%)
Mestinon 11/27 (40.7%) 2/8 (25.0%)
SSRI — selective serotonin reuptake inhibitors; NERI — norepine-
phrine reuptake inhibitors
Table 1. Clinical features of patients with hyper-
adrenergic postural orthostatic tachycardia.
Age (years) 39 ± 11
Sex (female) 24 (88.9%)
Race (Caucasian) 22 (81.5%)
Co-morbidity:
Hypertension 9 (33.3%)
Diabetes mellitus 2 (7.4%)
Coronary artery disease 2 (7.4%)
Migraine 8 (29.6%)
Joint hypermobility syndrome 5 (18.5%)
Mitochondrial cytopathy 1 (3.7%)
Precipitating event:
Trauma 1 (3.7%)
Pregnancy 3 (12.5%)
Viral infection 3 (11.1%)
Symptoms:
Fatigue 14 (51.9%)
Orthostatic palpitation 13 (48.2%)
Orthostatic hypertension 5 (18.5%)
Dizziness/pre-syncope 16 (59.3%)
Syncope 11 (40.7%)
Anxiety 18 (67%)
Tremulousness 18 (67%)
Excessive sweating 14 (52%)
Nausea 9 (33%)
Diarrhea 10 (35%)
Bloating 9 (33%)
530
Cardiology Journal 2011, Vol. 18, No. 5
www.cardiologyjournal.org
Later investigations revealed that POTS is better
understood as a physiological state most common-
ly due to an inability of the peripheral vasculature
to maintain adequate resistance in the face of ortho-
static stress, allowing for excessive pooling of blood
in the more dependent areas of the body [1, 13, 14].
The resultant functional decline in circulatory vo-
lume elicits a compensatory increase in HR and myo-
cardial contractility. While compensatory in mild
cases, this mechanism is unable to fully compen-
sate in more severe cases, resulting in a reduction
in effective circulation and varying degrees of ce-
rebral hypoperfusion. Later investigations revealed
that POTS is not a single condition, but rather
a heterogeneous group of disorders resulting in
a similar physiological state [8, 13–15].
Clinical findings of hyperadrenergic
POTS in our series
Precipitating events. The less common form
of primary POTS, the hyperadrenergic form, tends
to have a gradual and progressive onset of symp-
toms as opposed to an abrupt onset [2, 16]. In our
study, one patient had onset years after traumatic
brain injury, three had symptoms following preg-
nancy, and another three had an onset of symptoms
following a viral illness.
Symptoms of POTS. Hyperadrenergic POTS
patients report significant tremor, anxiety, and cold
sweaty extremities when upright. Many will report
a significant increase in urinary output after being
upright for even a short period of time, and over half
suffer from true migraine headaches. In our series,
55–65% of patients reported symptoms of hyper-
adrenergic state in the form of anxiety, tremulousness
and excessive sweating. Orthostatic palpitations and
pre-syncope/dizziness were reported in 50–60% of
the patients. Fatigue was one of the commonest
symptoms reported in our patient series and synco-
pe was also reported in 40%. Some patients with
POTS may experience syncope in the absence of
significant decline in blood pressure. A sudden in-
crease in cerebrovascular resistance resulting in
decline in cerebral oxygenation that occurs in the
presence of orthostatic stress has also been report-
ed in these patients [17–20]. The higher incidence
of syncope and fatigue may be because of the selec-
tion bias in this study as many of these patients had
been referred from various centers for a second opi-
nion regarding diagnosis and management and were
often difficult to treat with refractory symptoms.
Gastrointestinal symptoms were reported in
almost 30% of the patients in this study. There have
been reports of gastrointestinal symptoms in pa-
tients suffering from POTS. Patients with hypera-
drenergic forms tend to have diarrhea rather than
constipation [2, 7]. In our series, almost 30% of pa-
tients had gastrointestinal symptoms in form of
nausea, bloating and diarrhea.
In our study, most patients demonstrated
symptoms of adrenergic overactivity in the form of
palpitations, tremulousness and almost one third of
our patients were hypertensive, receiving more
than two medications to control their blood pres-
sure. Almost 20% of our patients demonstrated
orthostatic rise in their blood pressure of more than
20 mm Hg. In some ways the symptoms patients
experience are suggestive of pheochromocytoma,
although no patient had evidence of this.
The patients suffering from hyperadrenergic
variant of POTS appear to have an increased cen-
trally mediated drive of norepinephrine or a defect
in norepinephrine reuptake, resulting in increased
availability of norepinephrine at the synaptic junc-
tions. Beta-blockers and centrally acting sym-
patholytics like clonidine, by counteracting the ex-
cess norepinephrine either by decreasing the cen-
trally mediated release or by receptor blockage, may
result in a substantial decline in norepinephrine
mediated effects [1, 2, 8, 15, 16].
Future perspective
There has been a substantial increase in the
efforts to understand the pathophysiology and etio-
logy of POTS. Recent research has shown that this
syndrome may have multiple etiologies, and we now
know that POTS can have multiple variants result-
ing from these multiple etiologies including partial
dysautonomia [3] centrally mediated hyperadren-
ergic stimulation [8], norepinephrine transporter
dysfunction [16], autoimmune anti body against
cholinesterase receptors [21], POTS associated
with deconditioning [22] and hypovolumia [23].
A recently published study reported that POTS may
be a manifestation of autonomic cardiac neuropathy
[24]. POTS has been reported after traumata [25]
and infections [26] as well.
The clinical profile of our patients was similar
to the patients reported in other studies. Also our
observations that beta-blockers and centrally act-
ing sympatholytics work better in patients pre-
sumed to have hyperadrenergic variant of POTS
were consistent with those in other series [2, 7].
Conclusions
Patients of hyperadrenergic POTS should be
identified and differentiated from those with neu-
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ropathic POTS. These patients are usually difficult
to treat and there are no standardized treatment
protocols known at this time for patients with hy-
peradrenergic POTS. A randomized control trail in
future may help evaluate the role of optimal thera-
py in these patients.
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